Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Disease Characteristics, Treatment Patterns, and Outcomes of Follicular Lymphoma in Patients 40 Years of Age and Younger: An Analysis from the National LymphoCare Study

Carla Casulo, MD, Michelle Byrtek, PhD, Keith L Dawson, DNP, MS, Xiaolei Zhou, MS, Christopher R. Flowers, MD, Charles M. Farber, MD PhD, John D Hainsworth, MD, James R Cerhan, MD PhD, Brian K Link, MD, Jonathan W Friedberg, MD

Blood (2014) 124 (21): 3044.

https://doi.org/10.1182/blood.V124.21.3044.3044

Published: 2014

Journal Articles

Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study

Carla Casulo, MD, Michelle Byrtek, PhD, Keith L. Dawson, DNP, RN, Xiaolei Zhou, MS, Charles Farber, MD, Christopher R. Flowers, MD, MS, John D. Hainsworth, MD, Brian K Link, MD, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 510.

https://doi.org/10.1182/blood.V122.21.510.510

Published: 2013

Journal Articles

Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial.

Ian W. Flinn, MD, PhD, Mark Mainwaring, MD, PhD, Nancy Peacock, MD, Dianna Shipley, MD, Edward Arrowsmith, MD, MPH, Michael R. Savona, MD, FACP, John D. Hainsworth, MD, Jesus G. Berdeja, MD

Blood (2012) 120 (21): 2748.

https://doi.org/10.1182/blood.V120.21.2748.2748

Published: 2012

Journal Articles

Rituximab +/− Bevacizumab for Patients with Previously Treated Follicular Non-Hodgkins Lymphoma: A Randomized Phase II Trial of the Sarah Cannon Research Institute.

John D. Hainsworth, MD, Dana S. Thompson, MD, F. Anthony Greco, MD, Eric Raefsky, MD, Scott Lunin, MD, James Reeves, Jr., MD, Ian W. Flinn, MD, PhD

Blood (2012) 120 (21): 2749.

https://doi.org/10.1182/blood.V120.21.2749.2749

Published: 2012

Journal Articles

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Ian W. Flinn, MD, PhD, William N. Harwin, MD, Patrick Ward, MD, PhD, Habib H. Doss, MD, Steven W. Papish, MD, John D. Hainsworth, MD, Jesus G. Berdeja, MD, John C. Byrd, MD

Blood (2012) 120 (21): 719.

https://doi.org/10.1182/blood.V120.21.719.719

Published: 2012

Journal Articles

Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute

Ian W. Flinn, MD, PhD, R. Seth Cooper, MD, Dana S. Thompson, MD, Jamie K. Waselenko, MD, James Reeves, Jr., MD, Rudolph L. Wise, MD, John D. Hainsworth, MD, Jesus G. Berdeja, MD

Blood (2012) 120 (21): 715.

https://doi.org/10.1182/blood.V120.21.715.715

Published: 2012

Journal Articles

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,

Ian W. Flinn, MD, PhD, William N. Harwin, MD, Inés M. Macias-Pérez, PhD, Patrick S. Tucker, MS, David M. Waterhouse, MD, Steven W. Papish, MD, Jeffrey A. Jones, MD, MPH, John D. Hainsworth, MD, John C. Byrd, MD

Blood (2011) 118 (21): 3912.

https://doi.org/10.1182/blood.V118.21.3912.3912

Published: 2011

Journal Articles

A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis

Jesus G. Berdeja, MD, Daniel R. Couriel, MD, Patrick Murphy, MD, Ralph V. Boccia, MD, Victor Priego, MD, John D. Hainsworth, MD, Inés M. Macias-Pérez, PhD, Ian W. Flinn, MD, PhD

Blood (2011) 118 (21): 2943.

https://doi.org/10.1182/blood.V118.21.2943.2943

Published: 2011

Journal Articles

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Ian W. Flinn, MD, PhD, Evan Lang, MD, Eric Raefsky, MD, Ralph Boccia, MD, Inés M. Macias-Pérez, PhD, Howard A. Burris, III, MD, John D. Hainsworth, MD

Blood (2010) 116 (21): 4015.

https://doi.org/10.1182/blood.V116.21.4015.4015

Published: 2010

Journal Articles

Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Ian W. Flinn, MD, PhD, Jesus G. Berdeja, MD, Jamie K. Waselenko, MD, R. Seth Cooper, MD, Jia Bi, MD, Kent Shih, MD, Habib H. Doss, MD, Natalie Dickson, MD, Dana S. Thompson, MD, Howard A. Burris, III, MD, John D. Hainsworth, MD

Blood (2010) 116 (21): 2461.

https://doi.org/10.1182/blood.V116.21.2461.2461

Published: 2010

Journal Articles

Role of Different Frontline Regimens in Achieving Complete Response in Follicular Lymphoma: A Meta-Analysis of CR Rate and Its Relation to Hazard Rate for Disease Progression.

M. Wayne Saville, John P. Leonard, John D. Hainsworth, Mitchell R. Smith, Mohamed Darif, Craig Park, Stephen J. Schuster

Blood (2006) 108 (11): 2754.

https://doi.org/10.1182/blood.V108.11.2754.2754

Published: 2006

Journal Articles

Long-Term Followup of Patients with Follicular Lymphoma (FL) Treated with Two Years of Maintenance Rituximab: Response to Rituximab Retreatment at Progression.

John D. Hainsworth, MD, Christina Meng, David R. Spigel, M.D., Eric L. Raefsky, M.D., John H. Barton, M.D., F. Anthony Greco, M.D.

Blood (2006) 108 (11): 4723.

https://doi.org/10.1182/blood.V108.11.4723.4723

Published: 2006

Journal Articles

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

John D. Hainsworth, Howard A. Burris, III, Lisa H. Morrissey, Sharlene Litchy, Daniel C. Scullin, Jr, James D. Bearden, III, Paul Richards, F. Anthony Greco

Blood (2000) 95 (10): 3052–3056.

https://doi.org/10.1182/blood.V95.10.3052

Published: 2000

NARROW

Disease Characteristics, Treatment Patterns, and Outcomes of Follicular Lymphoma in Patients 40 Years of Age and Younger: An Analysis from the National LymphoCare Study

Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study

Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial.

Rituximab +/− Bevacizumab for Patients with Previously Treated Follicular Non-Hodgkins Lymphoma: A Randomized Phase II Trial of the Sarah Cannon Research Institute.

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,

A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

Role of Different Frontline Regimens in Achieving Complete Response in Follicular Lymphoma: A Meta-Analysis of CR Rate and Its Relation to Hazard Rate for Disease Progression.

Long-Term Followup of Patients with Follicular Lymphoma (FL) Treated with Two Years of Maintenance Rituximab: Response to Rituximab Retreatment at Progression.

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only